Romiplostim administration shows reduced megakaryocyte response-capacity and increased myelofibrosis in a mouse model of MYH9-RD

Blood

Volumn 119, Issue 14, 2012, Pages 3333-3341

  Léon, Catherine ^a   Evert, Katja ^b   Dombrowski, Frank ^b   Pertuy, Fabien ^a   Eckly, Anita ^a   Laeuffer, Patricia ^a   Gachet, Christian ^a   Greinacher, Andreas ^b  

^a INSERM   (France)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN IB; GLYCOPROTEIN VI; ROMIPLOSTIM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; MALE; MEGAKARYOCYTE; MICROCIRCULATION; MOUSE; MYELOFIBROSIS; MYH9 RELATED DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 84859567130     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-373811     Document Type: Article

References (31)

1. Seri M, Pecci A, Di Bari F, et al. Myh9-related disease: May-Hegglin anomaly, Sebastian syndrome, Fechtner syndrome, and Epstein syndrome are not distinct entities but represent a variable expression of a single illness. Medicine (Baltimore). 2003;82(3):203-215. (Pubitemid 36578709)
2. Althaus K, Greinacher A. Myh9-related platelet disorders. Semin Thromb Hemost. 2009;35(2):189-203.
3. Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of myh9-related inherited thrombocytopenias. Br J Haematol. 2011;154(2):161-74.
4. Eckly A, Rinckel JY, Laeuffer P, et al. Proplatelet formation deficit and megakaryocyte death contribute to thrombocytopenia in MYH9 knockout mice. J Thromb Haemost. 2010;8(10):2243-2251.
5. Pecci A, Malara A, Badalucco S, et al. Mega-karyocytes of patients with myh9-related thrombocytopenia present an altered proplatelet formation. Thromb Haemost. 2009;102(1):90-96.
6. Kuter DJ. Biology and chemistry of thrombopoietic agents. Semin Hematol. 2010;47(3):243-248.
7. Stasi R, Bosworth J, Rhodes E, Shannon MS, Willis F, Gordon-Smith EC. Thrombopoietic agents. Blood Rev. 2010;24(4-5):179-190.
8. Ghanima W, Bussel JB. Thrombopoietic agents in immune thrombocytopenia. Semin Hematol. 2010;47(3):258-265.
9. Pecci A, Gresele P, Klersy C, et al. Eltrombopag for the treatment of the inherited thrombocytopenia deriving from myh9 mutations. Blood. 2010;116(26):5832-5837.
10. Leon C, Eckly A, Hechler B, et al. Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion. Blood. 2007;110(9):3183-3191. (Pubitemid 350106310)
11. Hartley C, McElroy T, Molineux G, Begley G. The novel thrombopoietic agent AMG 531 is effective in pre-clinical models of chemo/radiotherapy induced thrombocytopenia. Proc Am Assoc Cancer Res. 2005;46:1233.
12. Leon C, Hechler B, Freund M, et al. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest. 1999;104(12):1731-1737. (Pubitemid 30053190)
13. Hsia CC, Hyde DM, Ochs M, Weibel ER. An official research policy statement of the American Thoracic Society/European Respiratory Society: standards for quantitative assessment of lung structure. Am J Respir Crit Care Med. 2010;181(4):394-418.
14. Dombrowski F, Stieger B, Beuers U. Tauroursodeoxycholic acid inserts the bile salt export pump into canalicular membranes of cholestatic rat liver. Lab Invest. 2006;86(2):166-174. (Pubitemid 43117596)
15. Eckly A, Strassel C, Freund M, et al. Abnormal megakaryocyte morphology and proplatelet formation in mice with megakaryocyte-restricted myh9 inactivation. Blood. 2009;113(14):3182-3189.
16. Zucker-Franklin D, Philipp CS. Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept. Am J Pathol. 2000;157(1):69-74. (Pubitemid 30641726)
17. McDunn S, Hartz W Jr, Ts'Ao C, Green D. Coronary thrombosis in a patient with May-Hegglin anomaly. Am J Clin Pathol. 1991;95(5):715-718.
18. Goto S, Kasahara H, Sakai H, et al. Functional compensation of the low platelet count by increased individual platelet size in a patient with May-Hegglin anomaly presenting with acute myocardial infarction. Int J Cardiol. 1998;64(2):171-177. (Pubitemid 28275557)
19. Selleng K, Lubenow LE, Greinacher A, Warkentin TE. Perioperative management of MYH9 hereditary macrothrombocytopenia (Fechtner syndrome). Eur J Haematol. 2007;79(3):263-268. (Pubitemid 47231172)
20. Kahr WH, Hinckley J, Li L, et al J. Mutations in NBEAL2, encoding a beach protein, cause gray platelet syndrome. Nat Genet. 2011;43(8):738-740.
21. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet alpha-granules. Nat Genet. 2011;43(8):732-734.
22. Albers CA, Cvejic A, Favier R, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet. 2011;43(8):735-737.
23. Pedersen NT. Occurrence of megakaryocytes in various vessels and their retention in the pulmonary capillaries in man. Scand J Haematol. 1978;21(5):369-375.
24. Levine RF, Eldor A, Shoff PK, Kirwin S, Tenza D, Cramer EM. Circulating megakaryocytes: delivery of large numbers of intact, mature megakaryocytes to the lungs. Eur J Haematol. 1993;51(4):233-246. (Pubitemid 24014153)
25. Fuentes R, Wang Y, Hirsch J, et al. Infusion of mature megakaryocytes into mice yields functional platelets. J Clin Invest. 2010;120(11):3917-3922.
26. Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK. Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood. 2004;104(12):3611-3617. (Pubitemid 39564435)
27. Di Pumpo M, Noris P, Pecci A, et al. Defective expression of GPIB/IX/V complex in platelets from patients with May-Hegglin anomaly and Sebastian syndrome. Haematologica. 2002;87(9):943-947.
28. Ruggeri ZM, Zarpellon A, Roberts JR, McClintock RA, Jing H, Mendolicchio GL. Unravelling the mechanism and significance of thrombin binding to platelet glycoprotein Ib. Thromb Haemost. 2010;104(5):894-902.
29. Ravanat C, Strassel C, Hechler B, et al. A central role of GPIb-IX in the procoagulant function of platelets that is independent of the 45-kda GPI-balpha N-terminal extracellular domain. Blood. 2010;116(7):1157-1164.
30. van Genderen PJ, van Vliet HH, Prins FJ, et al. Excessive prolongation of the bleeding time by aspirin in essential thrombocythemia is related to a decrease of large von Willebrand factor multimers in plasma. Ann Hematol. 1997;75(5-6):215-220. (Pubitemid 27525050)
31. Zhang Y, Conti MA, Malide D, et al. Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A. Blood. 2012;119(1):238-250.